PCRX

23.21

0.17% -0.04

Handel nachbörslich: 23.21

Pacira Biosciences Inc (PCRX)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$23.25

Offen:

$23.25

24-Stunden-Volumen:

584.35K

Relative Volume:

0.69

Marktkapitalisierung:

$1.13B

Einnahmen:

$681.75M

Nettoeinkommen (Verlust:

$70.47M

KGV:

16.01

EPS:

1.45

Netto-Cashflow:

$173.19M

1W Leistung:

-2.93%

1M Leistung:

-11.55%

6M Leistung:

+26.62%

1J Leistung:

+2.07%

1-Tages-Spanne:

$22.82

$23.55

1-Wochen-Bereich:

$22.82

$24.36

52-Wochen-Spanne:

$11.16

$27.98

Pacira Biosciences Inc Stock (PCRX) Company Profile

Firmenname

Pacira Biosciences Inc

Sektor

Healthcare (1166)

Branche

Drug Manufacturers - Specialty & Generic (83)

Telefon

650-242-8052

Adresse

2000 SIERRA POINT PARKWAY, BRISBANE, NJ

Mitarbeiter

790

Twitter

Nächster Verdiensttermin

2024-11-06

Neueste SEC-Einreichungen

PCRX's Discussions on Twitter

Vergleichen Sie PCRX mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
PCRX Pacira Biosciences Inc	23.21	1.13B	681.75M	70.47M	173.19M	1.45
RGC Regencell Bioscience Holdings Ltd	10.36	303.95B	0	-5.87M	-767.30K	-0.45
ZTS Zoetis Inc	159.08	74.39B	9.29B	2.52B	2.28B	5.57
HLN Haleon Plc Adr	10.26	48.97B	14.35B	1.85B	0	0.4023
TAK Takeda Pharmaceutical Co Adr	15.42	47.39B	30.08B	710.16M	4.45B	0.2182
TEVA Teva Pharmaceutical Industries Ltd Adr	17.05	20.17B	16.54B	-1.64B	749.00M	-1.45

Pacira Biosciences Inc Stock (PCRX) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-01-30	Hochstufung	Truist	Sell → Hold
2024-08-13	Herabstufung	Truist	Buy → Sell
2024-08-12	Herabstufung	JP Morgan	Overweight → Underweight
2024-08-12	Herabstufung	Piper Sandler	Overweight → Neutral
2024-08-12	Herabstufung	RBC Capital Mkts	Outperform → Sector Perform
2024-08-12	Herabstufung	Raymond James	Outperform → Mkt Perform
2024-07-03	Herabstufung	Barclays	Overweight → Equal Weight
2024-03-07	Fortgesetzt	JP Morgan	Overweight
2023-12-20	Eingeleitet	Raymond James	Outperform
2023-08-03	Hochstufung	TD Cowen	Market Perform → Outperform
2023-01-31	Fortgesetzt	Wedbush	Outperform
2022-10-21	Fortgesetzt	Jefferies	Buy
2022-01-03	Fortgesetzt	JP Morgan	Overweight
2021-07-26	Hochstufung	JP Morgan	Neutral → Overweight
2021-04-21	Fortgesetzt	JP Morgan	Neutral
2021-04-09	Eingeleitet	Berenberg	Buy
2021-04-07	Fortgesetzt	RBC Capital Mkts	Outperform
2021-02-11	Herabstufung	Northland Capital	Outperform → Market Perform
2021-01-21	Herabstufung	SVB Leerink	Outperform → Mkt Perform
2020-09-21	Hochstufung	Northland Capital	Market Perform → Outperform
2020-07-06	Bestätigt	Needham	Buy
2020-05-27	Eingeleitet	Guggenheim	Neutral
2020-04-07	Eingeleitet	Northland Capital	Outperform
2020-03-20	Hochstufung	SVB Leerink	Mkt Perform → Outperform
2020-02-24	Bestätigt	H.C. Wainwright	Buy
2020-01-24	Eingeleitet	SunTrust	Buy
2020-01-23	Eingeleitet	SunTrust	Buy
2019-11-06	Eingeleitet	BTIG Research	Buy
2019-06-11	Eingeleitet	Barclays	Overweight
2019-05-06	Hochstufung	Mizuho	Underperform → Neutral
2019-05-02	Hochstufung	Stifel	Sell → Hold
2019-02-01	Herabstufung	Mizuho	Neutral → Underperform
2018-08-06	Herabstufung	BofA/Merrill	Buy → Neutral
2018-04-09	Bestätigt	H.C. Wainwright	Buy
2018-03-21	Bestätigt	Mizuho	Neutral
2018-02-16	Herabstufung	Needham	Buy → Hold
2018-01-19	Eingeleitet	Seaport Global Securities	Buy
2018-01-04	Bestätigt	Canaccord Genuity	Buy
2018-01-03	Eingeleitet	Leerink Partners	Mkt Perform

Alle ansehen

Pacira Biosciences Inc Aktie (PCRX) Neueste Nachrichten

Jun 18, 2025

Is the Options Market Predicting a Spike in Pacira BioSciences Stock? - TradingView

Jun 18, 2025

Investors in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) Should Contact the Shareholders Foundation in Connection with Lawsuit - Newswire :) Press Release Distribution

Jun 18, 2025

Pacira BioSciences Debuts Inspiring New Film Highlighting - GlobeNewswire

Jun 18, 2025

Pacira BioSciences Debuts Inspiring New Film Highlighting One Patient’s Journey to Pain Relief and Innovation in Care at BIO 2025 - GlobeNewswire Inc.

Jun 18, 2025

PACIRA ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire

Jun 18, 2025

Jun 17, 2025

PACIRA ALERT: Bragar Eagel & Squire, P.C. is Investigating Pacira BioSciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - Business Upturn

Jun 17, 2025

Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRX) Shareholders to Inquire about Securities Investigation - ACCESS Newswire

Jun 17, 2025

Jun 16, 2025

When the Price of (PCRX) Talks, People Listen - news.stocktradersdaily.com

Jun 16, 2025

Jun 15, 2025

Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRX) And Encourages Shareholders to Connect - ACCESS Newswire

Jun 15, 2025

Rhumbline Advisers Sells 9,754 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) - Defense World

Jun 15, 2025

Jun 14, 2025

GAMMA Investing LLC Grows Stock Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX) - Defense World

Jun 14, 2025

Jun 13, 2025

Pacira Pharmaceuticals Stockholders Approve Amended Incentive Plan - TipRanks

Jun 13, 2025

Jun 12, 2025

Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRX) Stockholders to Inquire about Securities Investigation - ACCESS Newswire

Jun 12, 2025

Have Pacira BioSciences Insiders Been Selling Stock? - simplywall.st

Jun 12, 2025

Jun 11, 2025

Pacira (PCRX) Shares Promising Long-Term Data for Osteoarthritis Gene Therapy | PCRX Stock News - GuruFocus

Jun 11, 2025

Pacira BioSciences Unveils Three-Year Clinical Data - GlobeNewswire

Jun 11, 2025

Pacira BioSciences Unveils Three-Year Clinical Data Following a Single Local Administration of Investigational Gene Therapy, PCRX-201, in Patients with Moderate-to-Severe Osteoarthritis of the Knee - Yahoo Finance

Jun 11, 2025

Pacira BioSciences (NASDAQ:PCRX) Seems To Use Debt Quite Sensibly - simplywall.st

Jun 11, 2025

Jun 10, 2025

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRX) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire

Jun 10, 2025

Jun 08, 2025